June 11, 2020 07:06 AM EDT

A storied Chinese pharma partner of Bristol Myers, Amgen — and avid biotech supporter — plots HK IPO

A hefty pharma IPO is coming to Hong Kong.

Simcere isn’t one of the group of pre-revenue biotechs taking advantage of Hong Kong’s

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO